Endometrial markers of polycystic ovary syndrome (literature review)
https://doi.org/10.12737/article_5a3a0d6a897224.40594850
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disease in women and has a significant impact on various aspects of their health and the quality of life. The epidemiology of PCOS is well understood, while the prevalence of this syndrome depends on diagnostic criteria used, the characteristics of the population sample, and vary from 6-10 % to 15 % and higher. A number of studies suggest that the endometrium in women with PCOS differs from the normal endometrium morphologically and functionally. PCOS is associated with infertility problems, higher incidence of pregnancy complications and with increased risk of endometrial cancer, especially when obesity is present. The purpose of this review was to systematize the available data on molecular markers of endometrial pathology associated with PCOS. The information search was conducted using Internet resources (PubMed, EMBASE); literature sources for the period 1992-2016 were analyzed. Although the available information on the pathology of the endometrium is inconsistent, as a result of the analysis of published data, several mechanisms of endometrial disorders characteristic of PCOS have been identified: changes of hormonal effects (changes in hormone receptor expression, HOXA gene expression, changes in the synthesis of sex hormone binding globulin, enzymes involved in the metabolism of sex hormones in situ in the endometrium), hyperinsulinemia and disturbance of the glucose transport system, ratio of proinflammatory and antiinflammatory factors. Authors conclude that the majority of analyzed studies report an increased prevalence of histologically confirmed hyperplasia or endometrial cancer in women with PCOS. However, there are no clinical guidelines and approaches to prognosis of endometrial changes women with PCOS. It is still unclear if endometrial biopsy is necessary for all women with PCOS. The clinical significance of endometrial markers requires further investigation.
About the Authors
E. M. Sharifulin
Irkutsk Regional Clinical Hospital; Scientific Centre for Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
M. A. Sharifulin
Irkutsk Regional Clinical Hospital; Irkutsk State Medical Academy of Postgraduate Education - Branch Campus of the Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
L. V. Suturina
Scientific Centre for Family Health and Human Reproduction Problems
Russian Federation
Russian Federation
References
1. Apparao KB, Lovely LP, Gui Y, Lininger RA, Lessey BA. (2002). Elevated endometrial androgen receptor expression in women with polycystic ovarian syndrome. Biol Reprod, 66 (2), 297-304.
2. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. (2009). The androgen excess and PCOS society criteria for the polycystic ovary syndrome: the complete task force report, Fertil Steril, 91 (2), 456-488.
3. Bacallao K, Leon L, Gabler F, Soto E, Romero C, Valladares L, Vega M. (2008). In situ estrogen metabolism in proliferative endometria from untreated women with polycystic ovarian syndrome with and without endometrial hyperplasia. J Steroid Biochem Mol Biol, 110 (1-2), 163-169.
4. Balen A. (2001). Polycystic ovary syndrome and cancer. Hum Reprod Update, 7 (6), 522-525.
5. Cermik D, Selam B, Taylor HS. (2003). Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. J Clin Endocrinol Metab, 88 (1), 238-243.
6. Chen JC, Erikson DW, Piltonen TT, Meyer MR, Barragan F, McIntire RH, Tamaresis JS, Vo KC, Giudice LC, Irwin JC. (2013). Coculturing human endometrial epithelial cells and stromal fibroblasts alters cell-specific gene expression and cytokine production. Fertil Steril, 100 (4), 1132-1143.
7. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA. (2003). Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 88 (6), 2562-2568.
8. Cymbaluk A, Chudecka-Głaz A, Rzepka-Górska I. (2008). Leptin levels in serum depending on Body Mass Index in patients with endometrial hyperplasia and cancer. Eur J Obstet Gynecol Reprod Biol, 136 (1), 74-77.
9. Dorgan JF, Stanczyk FZ, Longcope C, Stephenson HE Jr, Chang L, Miller R, Franz C, Falk RT, Kahle L. (1997). Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev, 6 (3), 177-181.
10. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM. (2010). Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control, 21 (12), 2303-2308.
11. Giudice LC. (2006). Endometrium in PCOS: implantation and predisposition to endocrine CA. Best Pract Res Clin Endocrinol Metab, 20 (2), 235-244.
12. Goncharenko VM, Beniuk VA, Kalenska OV, Demchenko OM, Spivak MY, Bubnov RV. (2013). Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J, 4 (1), 24.
13. Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. (2015). Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol, 136 (1), 99-103.
14. Gregory CW, Wilson EM, Apparao KB, Lininger RA, Meyer WR, Kowalik A, Fritz MA, Lessey BA. (2002). Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab, 87 (6), 2960-2966.
15. Group ESHRE/ASRM-Sponsored PCOS Consensus Workshop. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril, 81 (1), 19-25.
16. Gruenigen VE, Gil KM, Frasure HE, Jenison EL, Hopkins MP. (2005). The impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol, 193 (4), 1369-1375.
17. Homburg R, Levy T, Berkovitz D, Farchi J, Feldberg D, Ashkenazi J, Ben-Rafael Z. (1993). Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertil Steril, 59 (3), 527-531.
18. Kurman RJ, McConnell TG. (2010). Precursors of endometrial and ovarian carcinoma. Virchows Arch, 456 (1), 1-12.
19. Lee AV, Jackson JG, Gooch JL, Hilsenbeck SG, Coronado-Heinsohn E, Osborne CK, Yee D. (1999). Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol, 13 (5), 787-796.
20. Li X, Feng Y, Lin JF, Billig H, Shao R. (2014). Endometrial progesterone resistance and PCOS. J Biomed Sci, 21, 2.
21. Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, Azziz R. (2016). Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and metaanalysis. Fertil Steril, 106 (06), 1510-1520.
22. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. (2016). Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril, 106 (01), 6-15.
23. MacLaughlan SD, Palomino WA, Mo B, Lewis TD, Lininger RA, Lessey BA. (2007). Endometrial expression of Cyr61: a marker of estrogenic activity in normal and abnormal endometrium. Obstet Gynecol, 110 (1), 146-154.
24. Maybin JA, Critchley HO, Jabbour HN. (2011). Inflammatory pathways in endometrial disorders. Mol Cell Endocrinol, 335 (1), 42-51.
25. Mutter GL, Zaino RJ, Baak JP, Bentley RC, Robboy SJ. (2007). Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. Int J Gynecol Pathol, 26 (2), 103-114.
26. Navaratnarajah R, Pillay OC, Hardiman P. (2008). Polycystic ovary syndrome and endometrial cancer. Semin Reprod Med, 26 (1), 62-71.
27. Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F. (2010). Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril, 94 (5), 1805-1811.
28. Peppard HR, Marfori J, Iuorno MJ, Nestler JE. (2001). Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care, 24 (6), 1050-1052.
29. Piltonen TT, Chen J, Erikson DW, Spitzer TL, Barragan F, Rabban JT, Huddleston H, Irwin JC, Giudice LC. (2013). Mesenchymal stem/progenitors and other endometrial cell types from women with polycystic ovary syndrome (PCOS) display inflammatory and oncogenic potential. J Clin Endocrinol Metab, 98 (9), 3765-3775.
30. Piltonen TT, Chen JC, Khatun M, Kangasniemi M, Liakka A, Spitzer T, Tran N, Huddleston H, Irwin JC, Giudice LC. (2015). Endometrial stromal fibroblasts from women with polycystic ovary syndrome have impaired progesterone-mediated decidualization, aberrant cytokine profiles and promote enhanced immune cell migration in vitro. Hum Reprod, 30 (5), 1203-1215.
31. Plaza F, Gabler F, Romero C, Vantman D, Valladares L, Vega M. (2010). The conversion of dehydroe-piandrosterone into androst-5-ene-3beta,17beta-diol (androstenediol) is increased in endometria from untreated women with polycystic ovarian syndrome. Steroids, 75 (12), 810-817.
32. Plaza-Parrochia F, Poblete C, Gabler F, Carvajal R, Romero C, Valladares L, Vega M. (2015). Expression of steroid sulfated transporters and 3ß-HSD activity in endometrium of women having polycystic ovary syndrome. Steroids, 104, 189-195.
33. Ruiz-Alonso M, Blesa D, Simón C. (2012). The genomics of the human endometrium. Biochim Biophys Acta, 1822 (12), 1931-1942.
34. Savaris RF, Groll JM, Young SL, DeMayo FJ, Jeong JW, Hamilton AE, Giudice LC, Lessey BA. (2011). Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. J Clin Endocrinol Metab, 96 (6), 1737-1746.
35. Schouten LJ, Goldbohm RA, van den Brandt PA. (2004). Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands Cohort Study. J Natl Cancer Inst, 96 (21), 1635-1638.
36. Siddle K. (2011). Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol, 47 (1), R1-10.
37. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM, Lu KH. (2006). Association between adiponectin, insulin resistance, and endometrial cancer. Cancer, 106 (11), 2376-2381.
38. Villavicencio A, Bacallao K, Avellaira C, Gabler F, Fuentes A, Vega M. (2006). Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol Oncol, 103 (1), 307-314.
39. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. (2012). Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod, 27 (10), 3067-3073.
40. Zaino RJ. (2000). Endometrial hyperplasia: is it time for a quantum leap to a new classification? Int J Gynecol Pathol, 19 (4), 314-321.
Review
For citations:
Sharifulin E.M., Sharifulin M.A., Suturina L.V. Endometrial markers of polycystic ovary syndrome (literature review). Acta Biomedica Scientifica. 2017;2(5(2)):21-27. (In Russ.) https://doi.org/10.12737/article_5a3a0d6a897224.40594850
Views:
732
.png)
Email this article 
